Contact Padideh Kamali-Zare
Title CEO


Summary: Darmiyan is committed to developing a platform for early diagnosis of neurodegenerative disorders, with precise quantification and localization of microscopic level changes in the brain. Using just a regular brain MRI, Darmiyan’s software platform can produce brain maps that detect Alzheimer’s disease related abnormality many years before the onset of clinical symptoms. 
Need: It is currently impossible to find a cure for Alzheimer’s disease without early detection. Over the past five years numerous multi-billion-dollar Alzheimer’s disease late phase clinical trials have failed. A potential reason being for inadvertently involving people who were 20 years or more into the pathological process. Thus, there is a tremendous need for early disease detection and to drastically improve candidate selection for clinical trials.
Solution: Darmiyan is currently the only developer of a non-invasive technology that is able to detect Alzheimer’s Disease early. 
Value: Darmiyan has developed a suite of proprietary software algorithms that can detect and quantify the earliest microscopic brain tissue changes in neurodegenerative disorders. This capability is vital as it can determine with 95% accuracy if patients recruited for clinical trials are a good fit; those whose brains are neither too healthy to respond to drugs, nor are too damaged already to respond.